• About
  • Privacy Policy
  • Terms Of Use
  • Contact
Tuesday, January 31, 2023
Pharma Info Nepal
  • Home
  • Loksewa
  • License
  • Questions
  • Vacancy
  • Downloads
  • Notice
No Result
View All Result
  • Home
  • Loksewa
  • License
  • Questions
  • Vacancy
  • Downloads
  • Notice
No Result
View All Result
Pharma Info Nepal
No Result
View All Result
Home Updates

WHO Recommends Two New Drugs to Treat COVID-19

WHO Recommends Two New Drugs to Treat COVID-19

Nabin Bista by Nabin Bista
January 15, 2022
in Updates
0
WHO Recommends Two New Drugs to Treat COVID-19
447
VIEWS
Share on FacebookShare on Twitter

WHO Recommends Two New Drugs to Treat COVID-19

WHO has recommended two new drugs for COVID-19, providing yet more options for treating the disease. The extent to which these medicines will save lives depends on how widely available and affordable they will be.

The first drug, baricitinib, is strongly recommended for patients with severe or critical COVID-19. It is part of a class of drugs called Janus kinase (JAK) inhibitors that suppress the overstimulation of the immune system. WHO recommends that it is given with corticosteroids.

Baricitinib is an oral drug, used in the treatment of rheumatoid arthritis. It provides an alternative to other arthritis drugs called Interleukin-6 receptor blockers, recommended by WHO in July 2021.

WHO has also conditionally recommended the use of a monoclonal antibody drug, sotrovimab, for treating mild or moderate COVID-19 in patients who are at high risk of hospitalization. This includes patients who are older, immunocompromised, having underlying conditions like diabetes, hypertension, and obesity, and those unvaccinated.

Sotrovimab is an alternative to casirivimab-imdevimab, a monoclonal antibody cocktail recommended by WHO in September 2021. Studies are ongoing on the effectiveness of monoclonal antibodies against Omicron but early laboratory studies show that sotrovimab retains its activity.

The panel of experts developing the guidelines also looked at two other drugs for severe and critical COVID-19: ruxolitinib and tofacitinib. Given their uncertain effects, WHO made a conditional recommendation against their use.

WHo recommendations, forming the eighth update of WHO’s living guidelines on therapeutics and COVID-19, are based on evidence from seven trials involving over 4,000 patients with non-severe, severe, and critical COVID-19.

WHO is in discussions with manufacturers to secure global supply capacity and equitable and sustainable access to the newly recommended therapeutics. The Access to COVID-19 Tools Accelerator (ACT-A) Therapeutics pillar has been engaging with pharmaceutical companies to seek comprehensive access plans for low- and middle-income countries, so that these treatments can be rapidly deployed everywhere, not just in rich countries. The ACT-A is also looking to expand licensing scope to make the products more affordable.

The two newly recommended drugs – baricitinib and sotrovimab – have been invited for WHO Prequalification, which assesses the quality, efficacy and safety of priority health products to increase access in lower income countries.

 



  • WHO issues Emergency Use Listing for COVAXIN 8th COVID-19 Vaccine
  • WHO Recommends Groundbreaking Malaria Vaccine for Children at Risk

 

Tags: COVIDMedicine Information
Previous Post

Novel Drug Approvals for 2021 FDA

Next Post

Department of Drug Administration – DDA Drug Recall Notice 

Nabin Bista

Nabin Bista

Hello, Thank You for visiting my blog I am Nabin Bista, Dedicated and self motivated young Pharmacist from Nepal. Blogging is my passion. I am studying B Pharmacy at Institute of Medicine - IOM. If you want me to write about any posts that you found confusing/difficult, please mention in the comments below.

Related Posts

FDA-Approved HIV Medicines

FDA Approved HIV Medicines

January 26, 2023
Combined Oral Contraceptives (COC)

Combined Oral Contraceptives (COC)

January 17, 2023
Novel Drug Approvals for 2022

Novel Drug Approvals for 2022

January 3, 2023
B Pharmacy Entrance Exam Notice 2079

B Pharmacy Entrance Exam Notice 2079

January 2, 2023
Load More
Next Post
Department of Drug Adminsitration (DDA)

Department of Drug Administration - DDA Drug Recall Notice 

Discussion about this post

Recommended

How Remdesivir Works in COVID-19

How Remdesivir Works in COVID-19

2 years ago
WHO Alert on 4 Indian Cough Syrups as 66 Gambian Kids Die

WHO Alert on 4 Indian Cough Syrups as 66 Gambian Kids Die

4 months ago

Don't Miss

FDA-Approved HIV Medicines

FDA Approved HIV Medicines

January 26, 2023
Combined Oral Contraceptives (COC)

Combined Oral Contraceptives (COC)

January 17, 2023
Nepal Pharmacy Council 21st Name Registration Exam Application Form Notice

Nepal Pharmacy Council 21st Name Registration Exam Application Form Notice

January 9, 2023
Nepal Pharmacy Counci Notice

Nepal Pharmacy Council Notice

January 5, 2023

About Pharma Info Nepal

Pharma Info Nepal (Nabin’s Blog) was initiated in 2019 with the aim of providing relevant and accurate information for pharmacy, nursing and other health professionals. Since then it is conveying health related educational and informational updates of Nepal. It serves as a source for learning materials on diverse topics relating to medicine intended basically for pharmacy and nursing students. It covers job opportunities, question collections for pharmacy license, nursing license as well as various competitive exams.

Our readers rely on us for the well referenced and latest updates collected from the reliable sites.

Follow us

  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Instagram

Information Reader

Contents (text, image, graphics, documents and other materials) published on this portal are collected from other relevant sources with the sole purpose of sharing information. Contents and features are subject to change and all rights reserved to Pharma info Nepal. The information presented on this web portal and its official social media handles have no affiliation to any organization that author is involved with either professionally or personally.

If you have found anything displayed incorrectly or have further suggestions on improving our effort, please do not hesitate to reach out at pharmainfonepal1@gmail.com !
We hope you find Pharma info Nepal a helpful site. Thanks !!!

Categories

  • B Pharmacy
  • Colleges
  • D Pharmacy
  • Downloads
  • License
  • Loksewa
  • M Pharmacy
  • Medicinal Chemistry
  • Notice
  • Nursing
  • Pharmacognosy
  • Pharmacology
  • Questions
  • Scholarship
  • Study Materials
  • Syllabus
  • Updates
  • Vacancy

DOWNLOADS

Pharmacy Book 

Pharmacy Act and Guidelines

About Pharma Info Nepal

About Admin

  • About
  • Privacy Policy
  • Terms Of Use
  • Contact

© 2021 Nabin's Blog

No Result
View All Result
  • Home
  • Loksewa
  • License
  • Questions
  • Vacancy
  • Downloads
  • Notice

© 2021 Nabin's Blog

error: